These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16025494)

  • 21. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B.
    Janssen HL; van Zonneveld M; Schalm SW
    N Engl J Med; 2004 Jun; 350(26):2719-20. PubMed ID: 15215493
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
    Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
    J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of single-using or combined-using lamivudine/interferon-alpha 1b on serum markers in patients with hepatitis B].
    Yan J; Zhang LS; Zhao XK
    Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):109-10. PubMed ID: 12648410
    [No Abstract]   [Full Text] [Related]  

  • 26. Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation.
    Protzer U; Goergen B; Hopf U; Neuhaus P; König V; Meyer zum Büschenfelde KH; Gerken G
    J Med Virol; 1996 Oct; 50(2):135-44. PubMed ID: 8915879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
    Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity.
    Günther S; Paulij W; Meisel H; Will H
    Virology; 1998 Apr; 244(1):146-60. PubMed ID: 9581787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
    Mutimer D
    J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
    [No Abstract]   [Full Text] [Related]  

  • 30. EASL Clinical Practice Guidelines: management of chronic hepatitis B.
    European Association For The Study Of The Liver
    J Hepatol; 2009 Feb; 50(2):227-42. PubMed ID: 19054588
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.
    Zöllner B; Sterneck M; Wursthorn K; Petersen J; Schröter M; Laufs R; Feucht HH
    J Clin Microbiol; 2005 May; 43(5):2503-5. PubMed ID: 15872296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The good and evil of flare: flares in hepatitis B virus chronic hepatitis.
    Massetto B; Menzaghi B; Giambelli C; Antinori S; Milazzo L
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):821-3. PubMed ID: 17700272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antiviral treatment of HBeAg positive chronic hepatitis B].
    Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):540. PubMed ID: 16042897
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pegylated interferon alpha in the treatment of chronic hepatitis B in HBe negative patients].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2006; 60(1):105-8. PubMed ID: 16758747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
    Urganci N; Gulec S; Dogan S; Nuhoglu A
    Int J Infect Dis; 2006 Nov; 10(6):453-7. PubMed ID: 17000127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Bigot G; Haagmans BL; Janssen HL
    J Clin Virol; 2008 Jun; 42(2):160-4. PubMed ID: 18359663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug therapy of hepatitis B and C].
    Färkkilä M
    Duodecim; 2003; 119(6):519-29. PubMed ID: 12708339
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic viral hepatitis--benefits of current therapies.
    Hoofnagle JH; Lau D
    N Engl J Med; 1996 May; 334(22):1470-1. PubMed ID: 8618588
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.